8852
-
International Journal of Nephrology and Renovascular Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Update on the diagnosis and management of acute kidney injury
Review
(3380) Views (1436) Full article downloads
Authors: Ali Akcay, Kultigin Turkmen, DongWon Lee, et al
Published Date September 2010
Volume 2010:3 Pages 129 - 140
DOI: http://dx.doi.org/10.2147/IJNRD.S8641
Ali Akcay, Kultigin Turkmen, DongWon Lee, Charles L EdelsteinDivision of Renal Diseases and Hypertension, University of Colorado and the Health Sciences Center, Aurora, Colorado, USA
Abstract: Acute kidney injury (AKI) is an independent risk factor for morbidity and mortality. This review provides essential information for the diagnosis and management of AKI. Blood urea nitrogen and serum creatinine are used for the diagnosis of AKI. The review also focuses on recent studies on the diagnosis of AKI using the RIFLE (R-renal risk, I-injury, F-failure, L-loss of kidney function, E-end stage kidney disease) and Acute Kidney Injury Network criteria, and serum and urine AKI biomarkers. Dialysis is the only Food and Drug Administration-approved therapy for AKI. Recent studies on the dose of dialysis in AKI are reviewed.
Keywords: acute kidney injury, biomarkers, interleukin-18
Readers of this article also read:
Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney
Nephrolithiasis-induced end stage renal disease
Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients
New and improved strategies for the treatment of gout
Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension
Diabetic microvascular complications: possible targets for improved macrovascular outcomes
Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis
Emerging drug combinations to optimize renovascular protection and blood pressure goals
Nephrolithiasis-induced end stage renal disease
Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients
New and improved strategies for the treatment of gout
Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension
Diabetic microvascular complications: possible targets for improved macrovascular outcomes
Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis
Emerging drug combinations to optimize renovascular protection and blood pressure goals
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Potential renovascular hypertension, space missions, and the role of magnesium
- The use of everolimus in renal-transplant patients
- Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
